Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · atopic eczema
1 finding from 1 review
Maternal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
It is very uncertain whether paracetamol changes maternal adverse events (up to 4 hours and at 6 hours) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the child ‐ Congenital malformations compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · Patients with osteoarthritis of the knee or hip
Tramadol alone probably leads to higher number of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Severe PPH (≥ 1000 mL) · pregnant women and their infants..
Vitamin D supplementation may leads to lower maternal adverse events: severe postpartum haemorrhage compared with placebo or no intervention (low certainty).
1 finding from 1 review
Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis
It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).
1 finding from 1 review
Any serious adverse event of treatment count of events · people with traumatic head injuries
Antiepileptic drugs showed no clear difference in any serious adverse event of treatment count of events compared with placebo or standard care (low certainty).
1 finding from 1 review
Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events Any serious or non‐serious adverse event · Individuals with autism spectrum disorder
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Any adverse events including hepatic and renal toxicity · people with SCD
1 finding from 1 review
Any adverse events including hepatic and renal toxicity · children with SCD
1 finding from 1 review
Any adverse events including hepatic and renal toxicity · people with SCD
1 finding from 1 review
no estimate extracted
80 participants
Low
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High